Dataset Information

Development of new fusion proteins for visualizing amyloid-? oligomers in vivo.

ABSTRACT: The intracellular accumulation of amyloid-? (A?) oligomers critically contributes to disease progression in Alzheimer's disease (AD) and can be the potential target of AD therapy. Direct observation of molecular dynamics of A? oligomers in vivo is key for drug discovery research, however, it has been challenging because A? aggregation inhibits the fluorescence from fusion proteins. Here, we developed A?1-42-GFP fusion proteins that are oligomerized and visualize their dynamics inside cells even when aggregated. We examined the aggregation states of A?-GFP fusion proteins using several methods and confirmed that they did not assemble into fibrils, but instead formed oligomers in vitro and in live cells. By arranging the length of the liker between A? and GFP, we generated two fusion proteins with "a long-linker" and "a short-linker", and revealed that the aggregation property of fusion proteins can be evaluated by measuring fluorescence intensities using rat primary culture neurons transfected with A?-GFP plasmids and A?-GFP transgenic C. elegans. We found that A?-GFP fusion proteins induced cell death in COS7 cells. These results suggested that novel A?-GFP fusion proteins could be utilized for studying the physiological functions of A? oligomers in living cells and animals, and for drug screening by analyzing A? toxicity.

SUBMITTER: Ochiishi T

PROVIDER: S-EPMC4793674 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Development of new fusion proteins for visualizing amyloid-β oligomers in vivo.

Ochiishi Tomoyo T Doi Motomichi M Yamasaki Kazuhiko K Hirose Keiko K Kitamura Akira A Urabe Takao T Hattori Nobutaka N Kinjo Masataka M Ebihara Tatsuhiko T Shimura Hideki H

Scientific reports 20160316

The intracellular accumulation of amyloid-β (Aβ) oligomers critically contributes to disease progression in Alzheimer's disease (AD) and can be the potential target of AD therapy. Direct observation of molecular dynamics of Aβ oligomers in vivo is key for drug discovery research, however, it has been challenging because Aβ aggregation inhibits the fluorescence from fusion proteins. Here, we developed Aβ1-42-GFP fusion proteins that are oligomerized and visualize their dynamics inside cells even ...[more]

PMID: 26982553

Similar Datasets

Project description:BackgroundThe lack of effective treatments for Alzheimer's disease (AD) reflects an incomplete understanding of disease mechanisms. Alterations in proteins involved in mitochondrial dynamics, an essential process for mitochondrial integrity and function, have been reported in AD brains. Impaired mitochondrial dynamics causes mitochondrial dysfunction and has been associated with cognitive impairment in AD. Here, we investigated a possible link between pro-inflammatory interleukin-1 (IL-1), mitochondrial dysfunction, and cognitive impairment in AD models.MethodsWe exposed primary hippocampal cell cultures to amyloid-β oligomers (AβOs) and carried out AβO infusions into the lateral cerebral ventricle of cynomolgus macaques to assess the impact of AβOs on proteins that regulate mitochondrial dynamics. Where indicated, primary cultures were pre-treated with mitochondrial division inhibitor 1 (mdivi-1), or with anakinra, a recombinant interleukin-1 receptor (IL-1R) antagonist used in the treatment of rheumatoid arthritis. Cognitive impairment was investigated in C57BL/6 mice that received an intracerebroventricular (i.c.v.) infusion of AβOs in the presence or absence of mdivi-1. To assess the role of interleukin-1 beta (IL-1β) in AβO-induced alterations in mitochondrial proteins and memory impairment, interleukin receptor-1 knockout (Il1r1-/-) mice received an i.c.v. infusion of AβOs.ResultsWe report that anakinra prevented AβO-induced alteration in mitochondrial dynamics proteins in primary hippocampal cultures. Altered levels of proteins involved in mitochondrial fusion and fission were observed in the brains of cynomolgus macaques that received i.c.v. infusions of AβOs. The mitochondrial fission inhibitor, mdivi-1, alleviated synapse loss and cognitive impairment induced by AβOs in mice. In addition, AβOs failed to cause alterations in expression of mitochondrial dynamics proteins or memory impairment in Il1r1-/- mice.ConclusionThese findings indicate that IL-1β mediates the impact of AβOs on proteins involved in mitochondrial dynamics and that strategies aimed to prevent pathological alterations in those proteins may counteract synapse loss and cognitive impairment in AD.

Project description:Introduction: ?-Amyloid protein (A?) putatively plays a seminal role in synaptic loss in Alzheimer's disease (AD). While there is no consensus regarding the synaptic-relevant species of A?, it is known that A? oligomers (A?Os) are noticeably increased in the early stages of AD, localizing at or within the synapse. In cell and animal models, A?Os have been shown to attach to synapses and instigate synapse dysfunction and deterioration. To establish the pathological mechanism of synaptic loss in AD, it will be important to identify the synaptic targets to which A?Os attach. Methods: An unbiased approach using far western ligand blots has identified three synaptic proteins to which A?Os specifically attach. These proteins (p100, p140, and p260) were subsequently enriched by detergent extraction, ultracentrifugation, and CHT-HPLC column separation, and sequenced by LC-MS/MS. P100, p140, and p260 were identified. These levels of A?Os targets in human AD and aging frontal cortexes were analyzed by quantitative proteomics and western-blot. The polyclonal antibody to A?Os was developed and used to block the toxicity of A?Os. The data were analyzed with one-way analysis of variance. Results: A?Os binding proteins p100, p140, and p260 were identified as Na/K-ATPase, synGap, and Shank3, respectively. ?3-Na/K-ATPase, synGap, and Shank3 proteins showed loss in the postsynaptic density (PSD) of human AD frontal cortex. In short term experiments, oligomers of A? inhibited Na/K-ATPase at the synapse. Na/K-ATPase activity was restored by an antibody specific for soluble forms of A?. ?3-Na/K-ATPase protein and synaptic ?-amyloid peptides were pulled down from human AD synapses by co-immunoprecipitation. Results suggest synaptic dysfunction in early stages of AD may stem from inhibition of Na/K-ATPase activity by A? oligomers, while later stages could hypothetically result from disrupted synapse structure involving the PSD proteins synGap and Shank3. Conclusion: We identified three A?O binding proteins as ?3-Na/K-ATPase, synGap, and Shank3. Soluble A? oligomers appear capable of attacking neurons via specific extracellular as well as intracellular synaptic proteins. Impact on these proteins hypothetically could lead to synaptic dysfunction and loss, and could serve as novel therapeutic targets for AD treatment by antibodies or other agents.

Dataset Information

Development of new fusion proteins for visualizing amyloid-? oligomers in vivo.

Publications

Development of new fusion proteins for visualizing amyloid-β oligomers in vivo.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets